Search
Now showing items 1-4 of 4
(Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2017)
Background: Approximately 15%–20% of all diagnosed breast cancers are characterized by amplified and overexpressed HER2 (= ErbB2). These breast cancers are aggressive and have a poor prognosis. Although improvements in ...
(Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2023)
Abstract Aberrant pro-survival signaling is a hallmark of cancer cells, but the response to chemotherapy is poorly understood. In this study, we investigate the initial signaling response to standard induction chemotherapy ...
(Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2023)
Current treatment selection for acute myeloid leukemia (AML) patients depends on risk stratification based on cytogenetic and genomic markers. However, the forecasting accuracy of treatment response remains modest, with ...
(Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2023)
Tumor heterogeneity is an important driver of treatment failure in cancer since therapies often select for drug-tolerant or drug-resistant cellular subpopulations that drive tumor growth and recurrence. Profiling the ...